Design, endpoints, enrollment, interim reads, and post‑market surveillance.
An article joins this feed when it matches these terms. Each one is also a search of its own.
Novartis has ended a mid-stage trial of Fabhalta for lupus nephritis, citing strategic considerations. The clinical-trial registry offered no further explanation and did not indicate whether safety or efficacy concerns played a role. · 6 sources across the spectrum on IJR News.
Two-thirds of enrolled patients carry the TNFR1 variant previously associated with greater treatment response in Phase 2 trials. Oculis (OCS) completed randomization in PREDICT-1, its first registrational trial of Licaminlimab for dry eye disease, with 176 patients enrolled. Two-thirds carry a specific TNFR1 genetic…
Collectively, the findings support the broad potential of ATNM-400 as a differentiated targeted radiotherapy across multiple large solid tumor indications, both as monotherapy and in combination with existing treatments In NSCLC, ATNM-400 demonstrated antitumor activity as monotherapy and enhanced activity…
The development of diffuse large B-cell lymphoma (DLBCL) in patients with a history of classical Hodgkin lymphoma (cHL) is a well-established but rarely documented event, particularly when it originates from the mixed cellularity subtype, an occurrence that has been minimally…
Disc Medicine will host a webcast on October 19, 2026, to discuss APOLLO Phase 3 trial results for bitopertin. The APOLLO Phase 3 trial evaluates the efficacy of bitopertin for treating erythropoietic porphyrias (EPP). The corporate webcast will be held on Monday, October 19, 2026, at…
Evercore Appoints Nigel Dawn and Naveen Nataraj as Co-Presidents No new safety signals were observed in the interim analysis; further development continues in biomarker-selected patients. Zentalis Pharmaceuticals (ZNTL) announced published interim survival data for azenosertib in platinum-resistant ovarian cancer from…
Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared on X: “Enjoyed presenting a case at the limbic, Australasian Lymphoma Alliance mantle cell lymphoma grand rounds this week – great discussion around 3 good cases. Mine was entitled Time for Blast Off.
A fulminant, disseminated, EBV-negative extranodal NK/T-cell lymphoma in a previously healthy infant was diagnosed only after death, underscoring the rarity and diagnostic complexity of pediatric ENKTCL. Subject of Research: Pathology and Oncology Research News Source: Nathaniel Bowman. (October 17, 2026). A…
Bioengineer.org Two rare autoimmune diseases of the central nervous system, once lumped together with multiple sclerosis, are finally getting the large-scale statistical scrutiny they deserve Neuromyelitis optica spectrum disorder (NMOSD) driven by antibodies against aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein…
Opus Genetics (IRD) was in the spotlight on Friday, after the U.S. Food and Drug Administration approved its eye drop for treating presbyopia, an age-related condition that makes it difficult to focus on nearby objects. The approval expands the use of…